Standard BioTools Inc
LAB1.320USD
+0.020+1.54%
Cierre 08/04, 16:00（ET）Cotizaciones retrasadas 15 min
500.39MCap. mercado
PérdidaP/E TTM
Más Datos de Standard BioTools Inc Compañía
Standard BioTools Inc. develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines. The Company's segments include Proteomics and Genomics. The Proteomics segment includes its instruments, consumables, software, and services based upon technologies used in the identification of proteins. The Genomics segment includes its instruments, consumables, software, and services based upon technologies used in the identification of genes and their functions. The Company provides insights in health and disease using its mass cytometry and microfluidics technologies, which serve applications in proteomics and genomic. It works with academic, government, pharmaceutical, biotechnology, plant and animal research, and clinical laboratories around the world, focusing on the needs in translational and clinical research, including oncology, immunology, and immunotherapy. The Company also provides differentiated multi-omics tools for research.
Información de la empresa
Símbolo de cotizaciónLAB
Nombre de la empresaStandard BioTools Inc
Fecha de salida a bolsaFeb 10, 2011
Director ejecutivoDr. Michael Egholm, Ph.D.
Número de empleados818
Tipo de seguridadOrdinary Share
Fin del año fiscalFeb 10
Dirección2 Tower Place
CiudadSOUTH SAN FRANCISCO
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal94080
Teléfono16502666000
Sitio Webhttps://www.standardbio.com/
Símbolo de cotizaciónLAB
Fecha de salida a bolsaFeb 10, 2011
Director ejecutivoDr. Michael Egholm, Ph.D.
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Fenel M. Eloi
Mr. Fenel M. Eloi
Independent Director
Independent Director
157.01K
+151.54%
Mr. Sean Mackay
Mr. Sean Mackay
Chief Business Officer
Chief Business Officer
105.09K
-37.30%
Mr. Eli D. Casdin
Mr. Eli D. Casdin
Independent Director
Independent Director
--
--
Mr. Troy Cox
Mr. Troy Cox
Independent Director
Independent Director
--
--
Ms. Kathy Hibbs
Ms. Kathy Hibbs
Independent Director
Independent Director
--
--
Dr. Michael Egholm, Ph.D.
Dr. Michael Egholm, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Hanjoon Alex Kim
Mr. Hanjoon Alex Kim
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Franklin R. (Frank) Witney, Ph.D.
Dr. Franklin R. (Frank) Witney, Ph.D.
Independent Director
Independent Director
--
--
Mr. Thomas (Tom) Carey
Mr. Thomas (Tom) Carey
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Fenel M. Eloi
Mr. Fenel M. Eloi
Independent Director
Independent Director
157.01K
+151.54%
Mr. Sean Mackay
Mr. Sean Mackay
Chief Business Officer
Chief Business Officer
105.09K
-37.30%
Mr. Eli D. Casdin
Mr. Eli D. Casdin
Independent Director
Independent Director
--
--
Mr. Troy Cox
Mr. Troy Cox
Independent Director
Independent Director
--
--
Ms. Kathy Hibbs
Ms. Kathy Hibbs
Independent Director
Independent Director
--
--
Dr. Michael Egholm, Ph.D.
Dr. Michael Egholm, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Desglose de ingresos
Divisa: USDActualizado: dom., 6 de jul
Divisa: USDActualizado: dom., 6 de jul
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
Por negocioUSD
Nombre
Ganancia
Proporción
Services
17.61M
43.16%
Consumables
14.45M
35.43%
Instruments
7.78M
19.07%
Other revenue
956.00K
2.34%
Por regiónUSD
Nombre
Ganancia
Proporción
Americas
18.97M
46.51%
Europe & Middle East & Africa (EMEA)
12.61M
30.90%
Asia-Pacific
9.21M
22.59%
Por negocio
Por región
Por negocioUSD
Nombre
Ganancia
Proporción
Services
17.61M
43.16%
Consumables
14.45M
35.43%
Instruments
7.78M
19.07%
Other revenue
956.00K
2.34%
Estadísticas de accionistas
Actualizado: sáb., 17 de may
Actualizado: sáb., 17 de may
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Casdin Capital, LLC
20.03%
Viking Global Investors LP
15.44%
BlackRock Institutional Trust Company, N.A.
5.88%
The Vanguard Group, Inc.
4.52%
Morgan Stanley Investment Management Inc. (US)
2.60%
Other
51.53%
Accionistas
Accionistas
Proporción
Casdin Capital, LLC
20.03%
Viking Global Investors LP
15.44%
BlackRock Institutional Trust Company, N.A.
5.88%
The Vanguard Group, Inc.
4.52%
Morgan Stanley Investment Management Inc. (US)
2.60%
Other
51.53%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor/Hedge Fund
29.08%
Hedge Fund
27.61%
Investment Advisor
14.98%
Individual Investor
1.52%
Venture Capital
0.62%
Research Firm
0.52%
Bank and Trust
0.22%
Pension Fund
0.12%
Private Equity
0.03%
Other
25.29%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
332
283.42M
74.62%
-28.16M
2025Q1
336
286.88M
75.60%
-24.96M
2024Q4
322
279.84M
75.18%
-22.14M
2024Q3
315
282.67M
78.53%
-14.93M
2024Q2
303
268.49M
74.97%
-14.97M
2024Q1
306
263.03M
71.99%
+131.65M
2023Q4
264
54.09M
66.99%
-14.10M
2023Q3
265
53.37M
67.31%
-13.39M
2023Q2
273
51.56M
65.50%
-19.05M
2023Q1
294
52.71M
66.75%
-21.93M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Casdin Capital, LLC
76.08M
20.03%
--
--
Apr 15, 2025
Viking Global Investors LP
58.65M
15.44%
--
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
22.35M
5.88%
-330.50K
-1.46%
Mar 31, 2025
The Vanguard Group, Inc.
17.17M
4.52%
+69.10K
+0.40%
Mar 31, 2025
Morgan Stanley Investment Management Inc. (US)
9.86M
2.6%
-5.85M
-37.23%
Mar 31, 2025
Geode Capital Management, L.L.C.
7.21M
1.9%
+230.24K
+3.30%
Mar 31, 2025
Long Focus Capital Management LLC
6.70M
1.76%
+6.70M
--
Mar 31, 2025
Tikvah Management LLC
6.55M
1.72%
--
--
Mar 31, 2025
State Street Global Advisors (US)
6.36M
1.67%
+69.13K
+1.10%
Mar 31, 2025
Nikko Asset Management Co., Ltd.
6.23M
1.64%
-384.70K
-5.81%
Mar 31, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 2 de ago
Actualizado: sáb., 2 de ago
Nombre
Proporción
Invesco NASDAQ Future Gen 200 ETF
0.54%
ARK Genomic Revolution ETF
0.36%
iShares Micro-Cap ETF
0.08%
iShares Biotechnology ETF
0.05%
iShares Russell 2000 Value ETF
0.03%
iShares Russell 2000 ETF
0.01%
Global X Russell 2000 ETF
0.01%
Proshares Ultra Russell 2000
0.01%
ProShares Hedge Replication ETF
0.01%
ProShares UltraPro Russell2000
0.01%
Ver más
Invesco NASDAQ Future Gen 200 ETF
Proporción0.54%
ARK Genomic Revolution ETF
Proporción0.36%
iShares Micro-Cap ETF
Proporción0.08%
iShares Biotechnology ETF
Proporción0.05%
iShares Russell 2000 Value ETF
Proporción0.03%
iShares Russell 2000 ETF
Proporción0.01%
Global X Russell 2000 ETF
Proporción0.01%
Proshares Ultra Russell 2000
Proporción0.01%
ProShares Hedge Replication ETF
Proporción0.01%
ProShares UltraPro Russell2000
Proporción0.01%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
